Proactive Investors - Run By Investors For Investors
Why invest in MDC?
Medlab Clinical Ltd: THE INVESTMENT CASE
INVESTMENT OVERVIEW

Medlab Clinical proceeding to stage II for cannabis cancer trial

The company will now proceed with stage II of the human clinical trial.
cannabis leaf and green tablets
INVESTMENT OVERVIEW: MDC The Big Picture
Stage I findings showed that NanaBis™ is safe indications confirm it helps with pain reduction

Medlab Clinical Ltd (ASX:MDC) has successfully completed stage I of the NanaBis™ human trial on cancer patients at Royal North Shore Hospital.

NanaBis™ is one of two of Medlab’s cannabis-based medicines which contains formulations of tetrahydrocannabinol (THC) and cannabidiol (CBD).

Medlab has received formal approval from the appropriate authority to proceed to stage II of the human cancer trial. 

Stage II of the clinical trial will focus on further safety but also tolerance and dose escalation.

READ: Medlab Clinical receives vital licence to export cannabis

Key data findings from stage I include that NanaBis™ is safe, is effective up to nine hours in a single dose, and early indications confirm it helps with pain reduction.

Medlab’s CEO Dr Sean Hall said: “These results confirm and validate our original hypothesis and offer a true alternative to current pain medications.

“I’m looking forward to data from stage II.

“Although pain measurement was not a key part of stage I, the early results of pain reduction while being administered NanaBis™ was very encouraging.”

In stage II, Medlab will continue with cancer patients but this time with unmanaged pain.

READ: Medlab Clinical receives positive early research results for NanoCelle™

In September, Medlab received preliminary results from research reviewing its patented delivery platform, NanoCelle™.

NanoCelle™ delivers medicine in a tiny particle form in a spray into the mouth and it is being tested using Medlab’s cannabis-based medicines, NanaBis™ and NanaBidial™.

The research concluded positively that molecules of the medicines, NanaBis™ and NanaBidial™ showed a consistent uniform pattern in nanoparticle form.

The type of work is critical as Medlab furthers its research endeavours for accepted, approved pharmaceuticals.

Join Proactive’s Crypto, Blockchain and Cannabis Telegram group here
View full MDC profile View Profile

Medlab Clinical Ltd Timeline

Related Articles

High Hampton Holdings set to add near term revenue to bottom line with Mojave Jane acquisition
November 13 2018
Mojave Jane is a California-licensed manufacturer of premium cannabis extracts and concentrates for buyers in the US state
A cannabis facility
December 02 2018
The Vancouver-based medicinal cannabis grower’s Queensland facility will be the world's largest greenhouse cannabis operation, covering a 99-acre site
cannabis
August 28 2018
Tidal Royalty provides capital to help grow licenced US cannabis firms in exchange for receiving a percentage of future top-line revenues.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use